Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2015

			Quoted Prices in Active Markets		Significant Other Observable Inputs		Unobservable Inputs
Description	June 30, 2015		(Level 1)		(Level 2)		(Level 3)
Assets:
Cash and cash equivalents	$	15,781	$	15,781	$	-	$	-
Total assets	$	15,781	$	15,781	$	-	$	-

Liabilities:
Warrants potentially settleable in cash	$	6,130	$	-	$	-	$	6,130
Total liabilities	$	6,130	$	-	$	-	$	6,130

	December 31, 2014		Quoted Prices in Active Markets		Significant Other Observable Inputs		Unobservable Inputs
Description	December 31, 2014		(Level 1)		(Level 2)		(Level 3)
Assets:
Cash and cash equivalents	$	3,970	$	3,970	$	-	$	-
Marketable securities		1,975		-		1,975		-
Total assets	$	5,945	$	3,970	$	1,975	$	-

Liabilities:
Warrants potentially settleable in cash	$	8,464	$	-	$	-	$	8,464
Total liabilities	$	8,464	$	-	$	-	$	8,464

	Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
	June 30, 2015			June 30, 2014
Balance , January 1,	$	8,464		$	23
Change in fair value of Teva option		-			(23	)
Estimated fair value of warrants assumed in merger on January 2, 2014		-			10,475
Estimated fair value of warrants issued in January 2014 common stock sale		-			3,696
Estimated fair value of warrants exchanged for common shares		(13,862	)		-
Change in fair value of warrants		11,528			(7,721	)
Balance at June 30, 2015 and 2014	$	6,130		$	6,450